Patritumab Deruxtecan (HER3-DXd)

patritumab deruxtecan · Daiichi Sankyo; Genentech

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Patritumab Deruxtecan (HER3-DXd), covering 2025-03-06 to 2025-03-06. Get the full timeline:

Most recent: Clinical Trial Update: Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT [Phase 2]